Trade Chugai Pharmaceutical Co., Ltd. - 4519 CFD
Add to favourite- Summary
- Historical Data
| Spread | 25.6 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.011658% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.010565% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | JPY | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Japan | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6767.6 |
| Open | 6888.3 |
| 1-Year Change | 55.13% |
| Day's Range | 6847.3 - 6897.1 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 20, 2024 | 6848.2 | -28.1 | -0.41% | 6876.3 | 6901.1 | 6838.4 |
| Sep 19, 2024 | 6767.6 | -68.9 | -1.01% | 6836.5 | 6900.2 | 6767.6 |
| Sep 18, 2024 | 6717.3 | -120.9 | -1.77% | 6838.2 | 6845.2 | 6650.7 |
| Sep 17, 2024 | 6862.4 | 7.1 | 0.10% | 6855.3 | 6872.4 | 6770.5 |
| Sep 13, 2024 | 6703.2 | -54.1 | -0.80% | 6757.3 | 6781.4 | 6671.6 |
| Sep 12, 2024 | 6833.2 | 185.7 | 2.79% | 6647.5 | 6874.3 | 6622.4 |
| Sep 11, 2024 | 6467.6 | -138.2 | -2.09% | 6605.8 | 6619.6 | 6429.7 |
| Sep 10, 2024 | 6585.5 | 95.1 | 1.47% | 6490.4 | 6699.0 | 6476.5 |
| Sep 9, 2024 | 6533.5 | 63.9 | 0.99% | 6469.6 | 6564.5 | 6388.5 |
| Sep 6, 2024 | 6584.5 | -41.5 | -0.63% | 6626.0 | 6752.5 | 6572.1 |
| Sep 5, 2024 | 6612.0 | -210.8 | -3.09% | 6822.8 | 6853.3 | 6612.0 |
| Sep 4, 2024 | 6908.1 | 26.9 | 0.39% | 6881.2 | 7001.1 | 6794.9 |
| Sep 3, 2024 | 7087.8 | 101.7 | 1.46% | 6986.1 | 7094.2 | 6966.7 |
| Sep 2, 2024 | 6925.1 | -382.6 | -5.24% | 7307.7 | 7321.7 | 6922.1 |
| Aug 30, 2024 | 7368.7 | -24.1 | -0.33% | 7392.8 | 7432.0 | 7254.5 |
| Aug 29, 2024 | 7351.7 | 3.0 | 0.04% | 7348.7 | 7408.5 | 7279.7 |
| Aug 28, 2024 | 7330.7 | -7.7 | -0.10% | 7338.4 | 7341.6 | 7206.5 |
| Aug 27, 2024 | 7326.7 | 161.6 | 2.26% | 7165.1 | 7350.1 | 7165.1 |
| Aug 26, 2024 | 7063.2 | -2.0 | -0.03% | 7065.2 | 7099.1 | 6844.4 |
| Aug 23, 2024 | 7216.8 | 24.0 | 0.33% | 7192.8 | 7363.8 | 7128.0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Chugai Pharmaceutical Co., Ltd. Company profile
About Chugai Pharmaceutical Co Ltd
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chugai Pharmaceutical Co Ltd revenues increased 27% to Y999.76B. Net income increased 41% to Y303B. Revenues reflect Net Sales increase of 27% to Y802.84B, Royalties and other operating revenues increase of 28% to Y196.92B. Dividend per share increased from Y55.00 to Y76.00. Basic Earnings per Share excluding Extraordinary Items increased from Y130.66 to Y184.29.
Equity composition
FY'03, the Co. changed FY end from March to December. FY'94-'02 WAS & FY'04 Q1 &Q3 WAs & O/S were estimated. 3/05 & 9/05, WAS, O/S, DPS were estimated. FY'06 Q3 & '07 Q1, Q3 WAS& DWAS were estimated, and its WAS was used as O/S. FY'08 1Q WAS & DWAS were estimated and WAS was used as o/s. FY'08 Q3 WAS estimated and used as o/s.
| Industry: | Pharmaceuticals (NEC) |
日本橋三井タワー15f
日本橋室町2-1-1
CHUO-KU
TOKYO-TO 103-8324
JP
News
RBA Preview: Rates to remain unchanged with inflation-fighting still the focus
RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.
12:27, 20 September 2024
BoE Preview: no change expected but forward guidance will be key
The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.
14:53, 19 September 2024
FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion
Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.
11:30, 19 September 2024
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com